FTC continues to scrutinize Orange Book patent listings

FTC Expands Patent Listing Challenges, Targeting More Than 300 ...

Improper Orange Book patent listings can delay cheaper generic alternatives from entering the market, keeping brand name drug prices ...

FTC continues to scrutinize Orange Book patent listings - DLA Piper

The Federal Trade Commission (FTC) sent its second set of warning letters to 10 companies disputing the accuracy or relevance of more than ...

Increased Scrutiny by Federal Trade Commission of Orange Book ...

The FTC's focus is on ensuring that only appropriate patents — those covering drug substances, drug products and methods of use — are listed. This scrutiny aims ...

US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents ...

FTC Continues to Ramp Up Scrutiny of Orange Book Patent Listings ... These patent listing challenges are just the latest step by the FTC, which ...

FTC Continues to 'Dispute' Orange Book Device Patent Listings, But ...

FTC Continues to 'Dispute' Orange Book Device Patent Listings, But Still No Antitrust Enforcement ... Over the last eight months, the US Federal ...

Increased Scrutiny by Federal Trade Commission of Orange Book ...

16 Currently, the FTC has limited its patent listing disputes to device patents, but it may broaden its scrutiny in the future. The FTC's April ...

FTC Challenges More Than 100 Patents as Improperly Listed in the ...

Listing patents in the Orange Book may negatively affect competitive conditions if listings are improper, as defined by law. “The FDA reminds ...

FTC Challenges More Patent Listings in the FDA's Orange Book

FTC's latest actions illustrate that Orange Book patent listings continue to be a priority for the agency. ... (FTC) has been busy scrutinizing ...

The Current Status of FTC's Orange Book Listings Challenge

... patent listings in the "Orange Book" of the U.S.. ... These companies, however, still maintain several patents that the FTC targeted for delisting ...

The FTC's Criticism of “Junk” Orange Book Filings - Ropes & Gray LLP

Making good on its promises, the FTC has continued its campaign against so-called “junk” patents listed in the FDA Orange Book, which Chair Khan ...

FTC continues to highlight FDA Orange Book patent listings

The FTC's argument that the patents are improperly listed in the Orange Book relies on the language of the statute, 21 USC 355(b)(1)(A)(viii), ...

FTC Issues Policy Statement on Brand Pharmaceutical ...

The FTC will scrutinize improper Orange Book patent listings as potential unfair methods of competition in violation of Section 5 of the FTC Act ...

An Antitrust Economist's Perspective on Recent FTC Scrutiny ...

However, the relative benefits and costs of listing additional patents may change as the FTC now scrutinizes Orange Book listings to identify ...

Primer: FTC Scrutinizes Orange Book Listings - AAF

While the FDA maintains the Orange Book, it does not police the information included, describing its role in patent listings as “ministerial,” ...

The FTC's Challenge to the Listing of Device Patents in the Orange ...

For the first wave of Warning Letters, six of the seventeen products did change the Orange Book listings while eleven remained unchanged. This ...

FTC Policy Statement Concerning Brand Drug Manufacturers ...

listing patents in the Orange Book may also be worthy of enforcement scrutiny from government ... The FTC will continue to use all its tools to halt.

FTC Challenges Over 100 Drug Product Patents Listed in FDA ...

The FTC's warning letters to manufacturers maintain the position that improperly listing patents in the Orange Book may violate antitrust laws.

Orange Book alert: Improper patent listings could be investigated as ...

This announcement is the latest indication that the FTC is closely monitoring Orange Book listings as part of its antitrust enforcement mission. In response, ...

Following Recent Policy Statement, FTC 'Disputes' 100+ Patent ...

Indeed, while the FTC characterizes its recent letters as “challenging” 100+ Orange Book patent listings, it notably did not bring any Section 5 ...

FTC Expands Orange Book Patent Listing Challenges

Initially, based on its September 2023 policy statement, FTC announced that it would “scrutinize improper Orange Book listings” and “use its ...